Milestone's etripamil meets in Phase II for PSVT

In May, Milestone Pharmaceuticals Inc. (Montreal, Quebec) reported data from the Phase II NODE-1 trial in 104 patients with a history of paroxysmal supraventricular tachycardia (PSVT) showing that 70, 105 and 140 mg doses of intranasal etripamil (MSP-2017) each met the primary endpoint of improving the percentage of patients successfully terminating PSVT induced in an electrophysiology laboratory to normal sinus rhythm within 15 minutes of induction vs. placebo (87%, 75% and 95%, respectively, vs. 35%, p<0.001, p<0.05 and p<0.001).

The trial enrolled patients who were expecting a catheter ablation to receive placebo or 35, 70, 105 or 140 mg etripamil. The lowest dose of etripamil led to conversion in 65% of patients. Across all 4 etripamil arms, median time to PSVT conversion ranged from 1.82 to 3.03 minutes...